Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture

Evaluate if crosslinked hard gelatin capsules (HGCs) having different in vitro dissolution profiles changed in vivo release times or altered bioavailability of a drug marker; assess if a two-tier dissolution test (with and without enzyme) predicted in vivo performance. Two classifications of stresse...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutical research 2000-05, Vol.17 (5), p.572-582
Hauptverfasser: DIGENIS, G. A, SANDEFER, E. P, PAGE, R. C, DOLL, W. J, GOLD, T. B, DARWAZEH, N. B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 582
container_issue 5
container_start_page 572
container_title Pharmaceutical research
container_volume 17
creator DIGENIS, G. A
SANDEFER, E. P
PAGE, R. C
DOLL, W. J
GOLD, T. B
DARWAZEH, N. B
description Evaluate if crosslinked hard gelatin capsules (HGCs) having different in vitro dissolution profiles changed in vivo release times or altered bioavailability of a drug marker; assess if a two-tier dissolution test (with and without enzyme) predicted in vivo performance. Two classifications of stressed HGCs were artificially produced by exposure to formaldehyde (HCHO). HGCs were categorized as, a) pass/pass (p/p) which met in vitro dissolution criterion (75% drug dissolution at 45 min), b) moderately crosslinked fail/pass (f/p) which failed dissolution criterion in the absence of enzymes and passed in the presence of enzymes, and c) severely crosslinked fail/fail (f/f) which failed in vitro standards with or without enzymes. A six-way, single dose bioequivalence study (n = 10) administered the three HGCs under the fasted and fed condition. In vivo capsule rupture and GI transit were monitored via gamma scintigraphy, and blood samples were collected through six hours. Each crosslinked HGC was bioequivalent to the control p/p capsule when using AUC(0-infinity) and Cmax for comparison. Mean in vivo disintegration of the p/p capsule was 7 +/- 5 min for the fasted condition and 11 +/- 7 min for the fed condition. In vivo rupture for the f/p capsule was 22 +/- 12 min and 23 +/- 11 min for the fasted and fed studies, respectively, while the f/f HGC ruptured at 31 +/- 15 min and 71 +/- 19 min under the fasted and fed condition, respectively. Onset of amoxicillin absorption was dependent on in vivo HGC rupture and subsequent entry of the released radioactive marker into the small intestine. Consequently, fasted Tmax values were significantly later for the f/p HGC (1.62 +/- 0.53 hr) and f/f HGC (1.85 +/- 0.58 hr) as compared to the p/p HGC (1.17 +/- 0.30 hr). Fed Tmax values were statistically different only for the f/f capsule (2.55 +/- 0.44 hr) where Tmax values for the p/p and f/p HGCs under the fed condition were 1.50 +/- 0.47 hr and 1.60 +/- 0.46 hr, respectively. A two-tier dissolution procedure that retested a crosslinked hard gelatin capsule with addition of gastric or intestinal enzymes provided an adequate in vitro indicator of the formulation's in vivo performance. The observed delays in the onset of amoxicillin absorption and Tmax for the severely crosslinked f/f HGC was attributed to delayed in vivo capsule rupture, however, this delay did not adversely change AUC(0-infinity) nor Cmax.
doi_str_mv 10.1023/A:1007568900147
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_222653766</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>432980721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c309t-1876832b082531e83cd518ef4cad3e43084aaf2404d46fc104e44b4ea446c7e83</originalsourceid><addsrcrecordid>eNpFkEFv1DAQhS0EotvCmRuyENfAOHYSh1upoFSqxAUkbqtZe5K6JHZqxyv2t_HncMsWTjOj-fTevGHslYB3Amr5_vyDAOiaVvcAQnVP2EY0nax6UD-esg10tap0p8QJO03pFgC06NVzdiJAay2h37DfH12gu-z2OJE3xNOa7YGHoTSRUiLL0Vvug_8332C0fKQJV-e5wSXliRLPyfmR4xx-OeOmqawwceQ25pHPGH9SfBAacZ6RJ-P86saIy82Br4Gb4AcXZ766mR6wyys-BVMcgr-_pajt3T48uvGYlzVHesGeDTglenmsZ-z750_fLr5U118vry7OrytTIq6V0F2rZb0DXTdSkJbGNkLToAxaSUqCVohDrUBZ1Q5GgCKldopQqdZ0hT9jb_7qLjHcZUrr9jbk6Ivltq7rtpFd2xbo9RHKu5nsdomu5D5sH19dgLdHAJPBaYjojUv_Odm3PWj5B_3ikOo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222653766</pqid></control><display><type>article</type><title>Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>DIGENIS, G. A ; SANDEFER, E. P ; PAGE, R. C ; DOLL, W. J ; GOLD, T. B ; DARWAZEH, N. B</creator><creatorcontrib>DIGENIS, G. A ; SANDEFER, E. P ; PAGE, R. C ; DOLL, W. J ; GOLD, T. B ; DARWAZEH, N. B</creatorcontrib><description>Evaluate if crosslinked hard gelatin capsules (HGCs) having different in vitro dissolution profiles changed in vivo release times or altered bioavailability of a drug marker; assess if a two-tier dissolution test (with and without enzyme) predicted in vivo performance. Two classifications of stressed HGCs were artificially produced by exposure to formaldehyde (HCHO). HGCs were categorized as, a) pass/pass (p/p) which met in vitro dissolution criterion (75% drug dissolution at 45 min), b) moderately crosslinked fail/pass (f/p) which failed dissolution criterion in the absence of enzymes and passed in the presence of enzymes, and c) severely crosslinked fail/fail (f/f) which failed in vitro standards with or without enzymes. A six-way, single dose bioequivalence study (n = 10) administered the three HGCs under the fasted and fed condition. In vivo capsule rupture and GI transit were monitored via gamma scintigraphy, and blood samples were collected through six hours. Each crosslinked HGC was bioequivalent to the control p/p capsule when using AUC(0-infinity) and Cmax for comparison. Mean in vivo disintegration of the p/p capsule was 7 +/- 5 min for the fasted condition and 11 +/- 7 min for the fed condition. In vivo rupture for the f/p capsule was 22 +/- 12 min and 23 +/- 11 min for the fasted and fed studies, respectively, while the f/f HGC ruptured at 31 +/- 15 min and 71 +/- 19 min under the fasted and fed condition, respectively. Onset of amoxicillin absorption was dependent on in vivo HGC rupture and subsequent entry of the released radioactive marker into the small intestine. Consequently, fasted Tmax values were significantly later for the f/p HGC (1.62 +/- 0.53 hr) and f/f HGC (1.85 +/- 0.58 hr) as compared to the p/p HGC (1.17 +/- 0.30 hr). Fed Tmax values were statistically different only for the f/f capsule (2.55 +/- 0.44 hr) where Tmax values for the p/p and f/p HGCs under the fed condition were 1.50 +/- 0.47 hr and 1.60 +/- 0.46 hr, respectively. A two-tier dissolution procedure that retested a crosslinked hard gelatin capsule with addition of gastric or intestinal enzymes provided an adequate in vitro indicator of the formulation's in vivo performance. The observed delays in the onset of amoxicillin absorption and Tmax for the severely crosslinked f/f HGC was attributed to delayed in vivo capsule rupture, however, this delay did not adversely change AUC(0-infinity) nor Cmax.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1023/A:1007568900147</identifier><identifier>PMID: 10888309</identifier><identifier>CODEN: PHREEB</identifier><language>eng</language><publisher>New York, NY: Springer</publisher><subject>Adult ; Amoxicillin - pharmacokinetics ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Capsules ; Cross-Linking Reagents ; Cross-Over Studies ; Digestive System - diagnostic imaging ; Digestive System - metabolism ; Excipients ; Food-Drug Interactions ; Gelatin ; General pharmacology ; Humans ; Male ; Medical sciences ; Penicillins - pharmacokinetics ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Radionuclide Imaging ; Therapeutic Equivalency</subject><ispartof>Pharmaceutical research, 2000-05, Vol.17 (5), p.572-582</ispartof><rights>2000 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers May 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c309t-1876832b082531e83cd518ef4cad3e43084aaf2404d46fc104e44b4ea446c7e83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1396908$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10888309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DIGENIS, G. A</creatorcontrib><creatorcontrib>SANDEFER, E. P</creatorcontrib><creatorcontrib>PAGE, R. C</creatorcontrib><creatorcontrib>DOLL, W. J</creatorcontrib><creatorcontrib>GOLD, T. B</creatorcontrib><creatorcontrib>DARWAZEH, N. B</creatorcontrib><title>Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><description>Evaluate if crosslinked hard gelatin capsules (HGCs) having different in vitro dissolution profiles changed in vivo release times or altered bioavailability of a drug marker; assess if a two-tier dissolution test (with and without enzyme) predicted in vivo performance. Two classifications of stressed HGCs were artificially produced by exposure to formaldehyde (HCHO). HGCs were categorized as, a) pass/pass (p/p) which met in vitro dissolution criterion (75% drug dissolution at 45 min), b) moderately crosslinked fail/pass (f/p) which failed dissolution criterion in the absence of enzymes and passed in the presence of enzymes, and c) severely crosslinked fail/fail (f/f) which failed in vitro standards with or without enzymes. A six-way, single dose bioequivalence study (n = 10) administered the three HGCs under the fasted and fed condition. In vivo capsule rupture and GI transit were monitored via gamma scintigraphy, and blood samples were collected through six hours. Each crosslinked HGC was bioequivalent to the control p/p capsule when using AUC(0-infinity) and Cmax for comparison. Mean in vivo disintegration of the p/p capsule was 7 +/- 5 min for the fasted condition and 11 +/- 7 min for the fed condition. In vivo rupture for the f/p capsule was 22 +/- 12 min and 23 +/- 11 min for the fasted and fed studies, respectively, while the f/f HGC ruptured at 31 +/- 15 min and 71 +/- 19 min under the fasted and fed condition, respectively. Onset of amoxicillin absorption was dependent on in vivo HGC rupture and subsequent entry of the released radioactive marker into the small intestine. Consequently, fasted Tmax values were significantly later for the f/p HGC (1.62 +/- 0.53 hr) and f/f HGC (1.85 +/- 0.58 hr) as compared to the p/p HGC (1.17 +/- 0.30 hr). Fed Tmax values were statistically different only for the f/f capsule (2.55 +/- 0.44 hr) where Tmax values for the p/p and f/p HGCs under the fed condition were 1.50 +/- 0.47 hr and 1.60 +/- 0.46 hr, respectively. A two-tier dissolution procedure that retested a crosslinked hard gelatin capsule with addition of gastric or intestinal enzymes provided an adequate in vitro indicator of the formulation's in vivo performance. The observed delays in the onset of amoxicillin absorption and Tmax for the severely crosslinked f/f HGC was attributed to delayed in vivo capsule rupture, however, this delay did not adversely change AUC(0-infinity) nor Cmax.</description><subject>Adult</subject><subject>Amoxicillin - pharmacokinetics</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Capsules</subject><subject>Cross-Linking Reagents</subject><subject>Cross-Over Studies</subject><subject>Digestive System - diagnostic imaging</subject><subject>Digestive System - metabolism</subject><subject>Excipients</subject><subject>Food-Drug Interactions</subject><subject>Gelatin</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Penicillins - pharmacokinetics</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Radionuclide Imaging</subject><subject>Therapeutic Equivalency</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpFkEFv1DAQhS0EotvCmRuyENfAOHYSh1upoFSqxAUkbqtZe5K6JHZqxyv2t_HncMsWTjOj-fTevGHslYB3Amr5_vyDAOiaVvcAQnVP2EY0nax6UD-esg10tap0p8QJO03pFgC06NVzdiJAay2h37DfH12gu-z2OJE3xNOa7YGHoTSRUiLL0Vvug_8332C0fKQJV-e5wSXliRLPyfmR4xx-OeOmqawwceQ25pHPGH9SfBAacZ6RJ-P86saIy82Br4Gb4AcXZ766mR6wyys-BVMcgr-_pajt3T48uvGYlzVHesGeDTglenmsZ-z750_fLr5U118vry7OrytTIq6V0F2rZb0DXTdSkJbGNkLToAxaSUqCVohDrUBZ1Q5GgCKldopQqdZ0hT9jb_7qLjHcZUrr9jbk6Ivltq7rtpFd2xbo9RHKu5nsdomu5D5sH19dgLdHAJPBaYjojUv_Odm3PWj5B_3ikOo</recordid><startdate>20000501</startdate><enddate>20000501</enddate><creator>DIGENIS, G. A</creator><creator>SANDEFER, E. P</creator><creator>PAGE, R. C</creator><creator>DOLL, W. J</creator><creator>GOLD, T. B</creator><creator>DARWAZEH, N. B</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20000501</creationdate><title>Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture</title><author>DIGENIS, G. A ; SANDEFER, E. P ; PAGE, R. C ; DOLL, W. J ; GOLD, T. B ; DARWAZEH, N. B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c309t-1876832b082531e83cd518ef4cad3e43084aaf2404d46fc104e44b4ea446c7e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Amoxicillin - pharmacokinetics</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Capsules</topic><topic>Cross-Linking Reagents</topic><topic>Cross-Over Studies</topic><topic>Digestive System - diagnostic imaging</topic><topic>Digestive System - metabolism</topic><topic>Excipients</topic><topic>Food-Drug Interactions</topic><topic>Gelatin</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Penicillins - pharmacokinetics</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Radionuclide Imaging</topic><topic>Therapeutic Equivalency</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DIGENIS, G. A</creatorcontrib><creatorcontrib>SANDEFER, E. P</creatorcontrib><creatorcontrib>PAGE, R. C</creatorcontrib><creatorcontrib>DOLL, W. J</creatorcontrib><creatorcontrib>GOLD, T. B</creatorcontrib><creatorcontrib>DARWAZEH, N. B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DIGENIS, G. A</au><au>SANDEFER, E. P</au><au>PAGE, R. C</au><au>DOLL, W. J</au><au>GOLD, T. B</au><au>DARWAZEH, N. B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture</atitle><jtitle>Pharmaceutical research</jtitle><addtitle>Pharm Res</addtitle><date>2000-05-01</date><risdate>2000</risdate><volume>17</volume><issue>5</issue><spage>572</spage><epage>582</epage><pages>572-582</pages><issn>0724-8741</issn><eissn>1573-904X</eissn><coden>PHREEB</coden><abstract>Evaluate if crosslinked hard gelatin capsules (HGCs) having different in vitro dissolution profiles changed in vivo release times or altered bioavailability of a drug marker; assess if a two-tier dissolution test (with and without enzyme) predicted in vivo performance. Two classifications of stressed HGCs were artificially produced by exposure to formaldehyde (HCHO). HGCs were categorized as, a) pass/pass (p/p) which met in vitro dissolution criterion (75% drug dissolution at 45 min), b) moderately crosslinked fail/pass (f/p) which failed dissolution criterion in the absence of enzymes and passed in the presence of enzymes, and c) severely crosslinked fail/fail (f/f) which failed in vitro standards with or without enzymes. A six-way, single dose bioequivalence study (n = 10) administered the three HGCs under the fasted and fed condition. In vivo capsule rupture and GI transit were monitored via gamma scintigraphy, and blood samples were collected through six hours. Each crosslinked HGC was bioequivalent to the control p/p capsule when using AUC(0-infinity) and Cmax for comparison. Mean in vivo disintegration of the p/p capsule was 7 +/- 5 min for the fasted condition and 11 +/- 7 min for the fed condition. In vivo rupture for the f/p capsule was 22 +/- 12 min and 23 +/- 11 min for the fasted and fed studies, respectively, while the f/f HGC ruptured at 31 +/- 15 min and 71 +/- 19 min under the fasted and fed condition, respectively. Onset of amoxicillin absorption was dependent on in vivo HGC rupture and subsequent entry of the released radioactive marker into the small intestine. Consequently, fasted Tmax values were significantly later for the f/p HGC (1.62 +/- 0.53 hr) and f/f HGC (1.85 +/- 0.58 hr) as compared to the p/p HGC (1.17 +/- 0.30 hr). Fed Tmax values were statistically different only for the f/f capsule (2.55 +/- 0.44 hr) where Tmax values for the p/p and f/p HGCs under the fed condition were 1.50 +/- 0.47 hr and 1.60 +/- 0.46 hr, respectively. A two-tier dissolution procedure that retested a crosslinked hard gelatin capsule with addition of gastric or intestinal enzymes provided an adequate in vitro indicator of the formulation's in vivo performance. The observed delays in the onset of amoxicillin absorption and Tmax for the severely crosslinked f/f HGC was attributed to delayed in vivo capsule rupture, however, this delay did not adversely change AUC(0-infinity) nor Cmax.</abstract><cop>New York, NY</cop><pub>Springer</pub><pmid>10888309</pmid><doi>10.1023/A:1007568900147</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0724-8741
ispartof Pharmaceutical research, 2000-05, Vol.17 (5), p.572-582
issn 0724-8741
1573-904X
language eng
recordid cdi_proquest_journals_222653766
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Adult
Amoxicillin - pharmacokinetics
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Capsules
Cross-Linking Reagents
Cross-Over Studies
Digestive System - diagnostic imaging
Digestive System - metabolism
Excipients
Food-Drug Interactions
Gelatin
General pharmacology
Humans
Male
Medical sciences
Penicillins - pharmacokinetics
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Radionuclide Imaging
Therapeutic Equivalency
title Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A46%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bioequivalence%20study%20of%20stressed%20and%20nonstressed%20hard%20gelatin%20capsules%20using%20amoxicillin%20as%20a%20drug%20marker%20and%20gamma%20scintigraphy%20to%20confirm%20time%20and%20GI%20location%20of%20in%20vivo%20capsule%20rupture&rft.jtitle=Pharmaceutical%20research&rft.au=DIGENIS,%20G.%20A&rft.date=2000-05-01&rft.volume=17&rft.issue=5&rft.spage=572&rft.epage=582&rft.pages=572-582&rft.issn=0724-8741&rft.eissn=1573-904X&rft.coden=PHREEB&rft_id=info:doi/10.1023/A:1007568900147&rft_dat=%3Cproquest_pubme%3E432980721%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222653766&rft_id=info:pmid/10888309&rfr_iscdi=true